Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Doctoral School for Medicine and Life Sciences, LCRC, UHasselt - Hasselt University, Diepenbeek, Belgium.
ESC Heart Fail. 2022 Dec;9(6):3858-3867. doi: 10.1002/ehf2.14056. Epub 2022 Aug 2.
To investigate the outcomes and associated costs of haemodynamic-guided heart failure (HF) management with a pulmonary artery pressure (PAP) sensor in a multicentre European cohort.
Data from all consecutive patients receiving a PAP sensor in Ziekenhuis Oost-Limburg, University Hospital Zurich and Sheffield Teaching Hospitals NHS Foundation Trust before January 2021 were collected. Medication changes, total number of HF hospitalizations and HF related health care costs (composed of HF hospitalizations, outpatient cardiology visits and monitoring costs) were compared between the pre-implantation and post-implantation period at 3, 6, and 12 months. PAP evolution post-implantation were grouped according to baseline mPAP ≥25 mmHg versus <25 mmHg and changes from baseline were analyzed via an area under the curve (AUC) analysis. A total of 48 patients received a PAP sensor (29 CardioMEMS and 19 Cordella devices) with a median follow-up of 19 (13-30) months. Mean age was 71 ± 10 years, 25.0% were female, 68.8% had a left ventricular ejection fraction < 50%, median NT-proBNP was 1801 (827-4503) pg/mL, and 89.6% were in NYHA class III. The number of diuretic therapy changes were non-significantly increased after 3 months (49 vs. 82; P = 0.284) and 6 months (82 vs. 127; P = 0.093) with a significant increase noted after 12 months (118 vs. 195; P = 0.005). The mPAP AUC decreased by -1418 mmHg-days for patients with a baseline mean PAP ≥ 25 mmHg. The number of HF hospitalizations was reduced for all patients after 6 (34 vs. 17; P = 0.014) and 12 months (48 vs. 29; P = 0.032). HF related health care costs were reduced from € 6286 to € 3761 at 6 months (P = 0.012) and from € 8960 to € 6167 at 12 months (P = 0.032).
Haemodynamic-guided HF management reduces HF hospitalizations and HF related health care costs in selected HF patients amongst different European health care systems.
在一个多中心的欧洲队列中,调查肺动脉压(PAP)传感器指导的心衰(HF)管理的结果和相关成本。
收集了 2021 年 1 月前在东利默里克医院、苏黎世大学医院和谢菲尔德教学医院 NHS 基金会信托接受 PAP 传感器的所有连续患者的数据。在植入前和植入后 3、6 和 12 个月比较药物治疗的变化、HF 住院次数和 HF 相关的医疗保健费用(由 HF 住院、门诊心脏病就诊和监测费用组成)。根据基线 mPAP ≥25mmHg 与 <25mmHg 以及从基线的变化,将植入后的 PAP 演变进行分组,并通过曲线下面积(AUC)分析进行分析。共 48 例患者接受 PAP 传感器(29 例 CardioMEMS 和 19 例 Cordella 装置),中位随访时间为 19(13-30)个月。平均年龄为 71±10 岁,25.0%为女性,68.8%左心室射血分数<50%,中位 NT-proBNP 为 1801(827-4503)pg/ml,89.6%为 NYHA Ⅲ级。在植入后 3 个月(49 次与 82 次;P=0.284)和 6 个月(82 次与 127 次;P=0.093)利尿剂治疗的改变次数无显著增加,12 个月后明显增加(118 次与 195 次;P=0.005)。基线平均 PAP≥25mmHg 的患者 mPAP AUC 下降-1418mmHg-days。所有患者在植入后 6 个月(34 次与 17 次;P=0.014)和 12 个月(48 次与 29 次;P=0.032)的 HF 住院次数减少。HF 相关的医疗保健费用在 6 个月时从€6286 降至€3761(P=0.012),在 12 个月时从€8960 降至€6167(P=0.032)。
在不同的欧洲医疗体系中,肺动脉压指导的心衰管理可减少选定的心衰患者的 HF 住院次数和 HF 相关的医疗保健费用。